Dr. Faizzan Ahmad joins the Strategic Advisory Board (SAB) at PAR Clinical.

 Press Release: Boston, Massachusetts: 9 December 2024

Dr. Faizzan Ahmad brings over 15 years of pioneering experience in regenerative medicine, longevity, and biotech finance, joining Cure8bio Ventures as a founding visionary and leader in “live” medicines development.

 Dr. Ahmad’s journey began with a first-class education at the University of Oxford, where his groundbreaking research in stem cell biology and cardiovascular pharmacology earned prestigious accolades and funding. His career trajectory has consistently blended deep scientific expertise with an entrepreneurial drive to bring transformative therapies to life.

Dr. Ahmad's scientific achievements have consistently broken new ground, from establishing a cutting-edge stem cell core facility in Doha to advancing neural regeneration at Johns Hopkins University. Transitioning to biotech finance, he has led numerous investments in innovative biotech companies and served on the boards of directors for pioneering ventures, playing a strategic role in shaping their growth and success.

Cure8bio Ventures envisions democratizing access to curative therapies by investing in transformational innovations at the intersection of cell therapy, gene therapy, and tissue engineering. His extensive expertise spans from bench research to strategic investments, ensuring the advancement of technologies that redefine patient care.

A recognized thought leader in regenerative medicine, Dr. Ahmad is equally passionate about fostering global innovation ecosystems. He has collaborated with stakeholders across Europe, the Middle East, Central Asia, and the US, championing the development of transformative therapies.

Beyond science and finance, Dr. Ahmad is an avid traveler and advocate for longevity research. He resides in New York, with a keen eye on the future of biotech innovation.

  

“Dr. Faizzan Ahmad’s leadership in regenerative medicine and biotech investments will further strengthen our vision of advancing transformative technologies and building a robust ecosystem for curative therapies. We are thrilled to have his strategic expertise and pioneering insights readily available to ensure we continue to build cost-efficient service models for our clients.”

Sid Parulkar, 

CEO, PAR Clinical